Ivabradine hydrochloride is a Small Molecule owned by Les Laboratoires Servier, and is involved in 39 clinical trials, of which 35 were completed, and 4 are ongoing.

Ivabradine hydrochloride is a heart rate lowering agent, acting by selective and specific inhibition of the cardiac pacemaker I(f) current that controls the spontaneous diastolic depolarisation in the sinus node and regulates heart rate. The drug candidate is If channel inhibitor that is carried by potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel. The cardiac effects are specific to the sinus node with no effect on intra-atrial, atrioventricular or intraventricular conduction times, nor on myocardial contractility or ventricular repolarisation.

The revenue for Ivabradine hydrochloride is expected to reach a total of $523m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Ivabradine hydrochloride NPV Report.

Ivabradine hydrochloride is originated and owned by Les Laboratoires Servier. Ono Pharmaceutical and Amgen are the other companies associated in development or marketing of Ivabradine hydrochloride.

Ivabradine hydrochloride Overview

Ivabradine hydrochloride (Procoralan/Corlentor, Coralan) is a benzazepine derivative acts as cardiotonic agent. It is formulated as film coated tablets, and solution for oral route of administration. Ivabradine hydrochloride is indicated for symptomatic treatment of chronic heart failure NYHA II to IV class with systolic dysfunction in adults and for the treatment of stable symptomatic heart failure due to dilated cardiomyopathy (DCM) in pediatric patients aged 6 months and older, who are in sinus rhythm with an elevated heart rate. It is also indicated for patients with chronic heart failure with sinus rhythm and baseline resting heart rate more than or 75 beats per minute.

The drug candidate is a new chemical entity. It was also under development for the treatment of dilated cardiomyopathy in pediatric patients.

Ono Pharmaceutical Overview

Ono Pharmaceutical focuses on the research, development, manufacture and sale of prescription pharmaceuticals and diagnostic reagents. Its product portfolio includes medicines for the treatment of type II diabetes, overactive bladder, osteoporosis, cancer, chemotherapy-induced nausea and vomiting, osteoporosis, Alzheimer’s disease, peripheral circulatory disorder, bronchial asthma and allergic rhinitis, among others. The company offers products in various formulations such as capsules, tablets, injections, patches, dry syrup and intravenous infusions. Ono Pharmaceutical has three manufacturing facilities; Joto Product Development Center, Yamaguchi Plant, and Fujiyama Plant. It offers products in the Americas, Europe, and Asia. Ono Pharmaceutical is headquartered in Osaka, Japan.

The company reported revenues of (Yen) JPY361,361 million for the fiscal year ended March 2022 (FY2022), an increase of 16.8% over FY2021. In FY2022, the company’s operating margin was 28.6%, compared to an operating margin of 31.8% in FY2021. In FY2022, the company recorded a net margin of 22.3%, compared to a net margin of 24.4% in FY2021. The company reported revenues of JPY109,979 million for the second quarter ended September 2022, an increase of 3.1% over the previous quarter.

Quick View – Ivabradine hydrochloride

Report Segments
  • Innovator (NME)
Drug Name
  • Ivabradine hydrochloride
Administration Pathway
  • Oral
Therapeutic Areas
  • Cardiovascular
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.